Pliant Therapeutics, Inc.

NasdaqGS:PLRX Stock Report

Market Cap: US$774.7m

Pliant Therapeutics Valuation

Is PLRX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PLRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate PLRX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PLRX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PLRX?

Key metric: As PLRX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for PLRX. This is calculated by dividing PLRX's market cap by their current book value.
What is PLRX's PB Ratio?
PB Ratio2.3x
BookUS$345.82m
Market CapUS$774.67m

Price to Book Ratio vs Peers

How does PLRX's PB Ratio compare to its peers?

The above table shows the PB ratio for PLRX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average2.9x
TERN Terns Pharmaceuticals
1.3x-14.7%US$475.7m
RAPP Rapport Therapeutics
2.5x-31.6%US$814.9m
OCS Oculis Holding
5.8x-4.7%US$630.0m
BIOA BioAge Labs
2.1x-15.6%US$659.6m
PLRX Pliant Therapeutics
2.3x-0.6%US$774.7m

Price-To-Book vs Peers: PLRX is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (2.9x).

Price to Book Ratio vs Industry

How does PLRX's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

24 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.39m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.92m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.50m
PLRX 2.3xIndustry Avg. 1.7xNo. of Companies24PB012345+
24 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: PLRX is expensive based on its Price-To-Book Ratio (2.3x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is PLRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PLRX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate PLRX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PLRX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$12.85
US$40.18
+212.7%
11.4%US$47.00US$32.00n/a11
Nov ’25US$14.52
US$40.18
+176.7%
11.4%US$47.00US$32.00n/a11
Oct ’25US$10.55
US$40.18
+280.9%
11.4%US$47.00US$32.00n/a11
Sep ’25US$13.29
US$41.36
+211.2%
10.2%US$47.00US$32.00n/a11
Aug ’25US$14.35
US$41.82
+191.4%
11.3%US$48.00US$32.00n/a11
Jul ’25US$10.86
US$41.82
+285.1%
11.3%US$48.00US$32.00n/a11
Jun ’25US$12.13
US$41.08
+238.7%
12.5%US$48.00US$32.00n/a12
May ’25US$12.66
US$43.00
+239.7%
13.6%US$54.00US$33.00n/a12
Apr ’25US$14.81
US$43.00
+190.3%
13.6%US$54.00US$33.00n/a12
Mar ’25US$16.54
US$42.67
+158.0%
12.4%US$50.00US$33.00n/a12
Feb ’25US$18.42
US$45.92
+149.3%
11.4%US$53.00US$34.00n/a12
Jan ’25US$18.11
US$45.92
+153.5%
11.4%US$53.00US$34.00n/a12
Dec ’24US$14.15
US$46.36
+227.7%
11.3%US$53.00US$34.00n/a11
Nov ’24US$14.84
US$48.67
+227.9%
13.9%US$63.00US$35.00US$14.5212
Oct ’24US$17.34
US$48.31
+178.6%
13.7%US$63.00US$35.00US$10.5513
Sep ’24US$16.80
US$48.08
+186.2%
13.7%US$63.00US$35.00US$13.2913
Aug ’24US$17.51
US$48.62
+177.6%
12.4%US$63.00US$40.00US$14.3513
Jul ’24US$18.12
US$48.62
+168.3%
12.4%US$63.00US$40.00US$10.8613
Jun ’24US$21.75
US$48.62
+123.5%
12.4%US$63.00US$40.00US$12.1313
May ’24US$22.31
US$48.92
+119.3%
13.2%US$63.00US$40.00US$12.6612
Apr ’24US$26.60
US$48.27
+81.5%
10.3%US$58.00US$40.00US$14.8111
Mar ’24US$31.43
US$49.09
+56.2%
11.6%US$60.00US$40.00US$16.5411
Feb ’24US$34.45
US$49.09
+42.5%
11.6%US$60.00US$40.00US$18.4211
Jan ’24US$19.33
US$41.91
+116.8%
15.7%US$53.00US$33.00US$18.1111
Dec ’23US$17.78
US$42.89
+141.2%
15.3%US$53.00US$33.00US$14.159
Nov ’23US$25.16
US$43.11
+71.3%
15.9%US$53.00US$33.00US$14.849

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%